## Alexander Stratigos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4784450/publications.pdf

Version: 2024-02-01

471509 223800 2,224 57 17 46 citations h-index g-index papers 59 59 59 3249 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Overview of guideline recommendations for the management of highâ€risk and advanced cutaneous squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 11-18.	2.4	8
2	Psychopathology and Alexithymia in Patients with Moderate-to-Severe Psoriasis: Development of a Novel Index with Prognostic Value. International Journal of Environmental Research and Public Health, 2022, 19, 4029.	2.6	1
3	<i>MC1R</i> variants in relation to naevi in melanoma cases and controls: a pooled analysis from the Mâ€SKIP project. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e135-e138.	2.4	3
4	A multicentre study of naevusâ€associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109.	1.5	13
5	Dermoscopy as a Tool in Differentiating Cutaneous Squamous Cell Carcinoma From Its Variants.  Dermatology Practical and Conceptual, 2021, 11, e2021050.	0.9	8
6	Novel Insights for Patients with Multiple Basal Cell Carcinomas and Tumors at High-Risk for Recurrence: Risk Factors, Clinical Morphology, and Dermatoscopy. Cancers, 2021, 13, 3208.	3.7	3
7	Not all melanomas are created equal: a review and call for more research into nodular melanoma. British Journal of Dermatology, 2021, 185, 700-710.	1.5	12
8	The impact of the COVIDâ€19 pandemic on diagnostic delay of skin cancer: a call to restart screening activities. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e836-e837.	2.4	9
9	A patient-centric dataset of images and metadata for identifying melanomas using clinical context. Scientific Data, 2021, 8, 34.	5.3	165
10	New insights into granulomatous mycosis fungoides (GMF): a single-center experience. European Journal of Cancer, 2021, 156, S69-S70.	2.8	1
11	Topical mechlorethamine in mycosis fungoides: a prospective clinical, histopathological, and molecular analysis of 13 cases. European Journal of Cancer, 2021, 156, S61-S62.	2.8	2
12	Vulvar pruritic papules in a 10â€yearâ€old girl. International Journal of Dermatology, 2021, , .	1.0	0
13	Botulinum toxin type A treatment is associated with improved social and psychological behavior: A retrospective study. Journal of Cosmetic Dermatology, 2021, , .	1.6	3
14	Comparing interest in indoor tanning among countries with different tanning bed regulations. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e218-e219.	2.4	0
15	The different faces of mycosis fungoides: results of a singleâ€center study. International Journal of Dermatology, 2020, 59, 314-320.	1.0	5
16	The evolving field of Dermatoâ€oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	2.4	22
17	Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2534-2540.	2.4	12
18	Stress and melanoma. Myth or reality?. British Journal of Dermatology, 2020, 183, 607-608.	1.5	1

#	Article	IF	CITATIONS
19	Occupational and nonâ€occupational allergic contact dermatitis to hair dyes in Greece. A 10â€year retrospective study. Contact Dermatitis, 2020, 83, 277-285.	1.4	16
20	428â€Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). , 2020, , .		5
21	Implementing polygenic risk scores in skin cancer: a step towards personalized risk prediction. British Journal of Dermatology, 2019, 181, 1117-1118.	1.5	3
22	Complete response is reversible upon vismodegib withdrawal and reâ€inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e187-e188.	2.4	2
23	A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors. Oncologist, 2019, 24, e755-e764.	3.7	11
24	A case of lymphomatoid papulosis, pityriasis lichenoides acuta, and mycosis fungoides coexistence. Australasian Journal of Dermatology, 2019, 60, e154-e156.	0.7	4
25	Brentuximab induced <scp>CD</scp> 30 <sup>+</sup> cutaneous lymphoma responded to antiâ€ <scp>PD</scp> 1 treatment. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e147-e148.	2.4	1
26	Dermoscopy of Common Inflammatory Disorders. Dermatologic Clinics, 2018, 36, 359-368.	1.7	26
27	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries Journal of Clinical Oncology, 2018, 36, e18609-e18609.	1.6	0
28	A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1295-1302.	2.4	67
29	From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots. British Journal of Dermatology, 2017, 177, 1485-1494.	1.5	16
30	Advanced squamous cell carcinoma of the axillae mimicking hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e421-e423.	2.4	7
31	Programmed cell death protein-1 inhibitors for immunotherapy of advanced nonmelanoma skin cancer: showing early promise. British Journal of Dermatology, 2016, 175, 1150-1151.	1.5	7
32	Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient. Multiple Sclerosis Journal, 2016, 22, 1630-1631.	3.0	12
33	Can hair reâ€growth be considered an early clinical marker of treatment resistance to Hedgehog inhibitors in patients with advanced basal cell carcinoma? A report of two cases. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1726-1729.	2.4	9
34	Polymorphous light eruption under the Mediterranean sun: a clinico-epidemiological and photobiological study. European Journal of Dermatology, 2016, 26, 304-306.	0.6	2
35	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: AÂPooled Analysis from the M-Skip Project. Journal of Investigative Dermatology, 2016, 136, 1914-1917.	0.7	16
36	Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis Journal of Clinical Oncology, 2016, 34, 9538-9538.	1.6	1

3

#	Article	IF	CITATIONS
37	Genetic epidemiology of malignant melanoma susceptibility. Melanoma Management, 2015, 2, 165-169.	0.5	2
38	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 1989-2007.	2.8	404
39	Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 2604-2608.	2.8	109
40	Replication of risk variants for psoriasis in a Southern European case–control study: correlation with clinical subphenotypes. British Journal of Dermatology, 2015, 173, 552-554.	1.5	3
41	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. European Journal of Cancer, 2015, 51, 2396-2403.	2.8	320
42	Demographic, behavioural and physicianâ€related determinants of early melanoma detection in a lowâ€incidence population. British Journal of Dermatology, 2014, 171, 832-838.	1.5	10
43	Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinoma. Journal of the American Academy of Dermatology, 2014, 70, 303-311.	1.2	110
44	Emerging trends in the epidemiology of melanoma. British Journal of Dermatology, 2014, 170, 11-19.	1.5	277
45	Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. British Journal of Dermatology, 2012, 167, 99-104.	1.5	70
46	Pregnancy during adalimumab use for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 738-739.	2.4	17
47	Etanercept: effectiveness and safety data of a retrospective study. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1113-1115.	2.4	9
48	Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families?. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1282-1287.	2.4	35
49	The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1455-1465.	2.4	82
50	Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with highâ€need psoriasis. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1413-1420.	2.4	14
51	Clinical characteristics and course of CD8+ cytotoxic variant of mycosis fungoides: a case series of seven patients. British Journal of Dermatology, 2009, 161, 826-830.	1.5	55
52	Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 968-969.	2.4	4
53	Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities. British Journal of Dermatology, 2008, 158, 431-432.	1.5	7
54	Sunscreens – what's important to know. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1110-1119.	2.4	118

#	Article	IF	CITATIONS
55	p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. British Journal of Dermatology, 2007, 156, 357-362.	1.5	27
56	Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-? therapy in a patient with psoriatic arthritis and psoriasis vulgaris. British Journal of Dermatology, 2007, 156, 1090-1091.	1.5	37
57	Immunophenotypic analysis of the p53 gene in nonâ€melanoma skin cancer and correlation with apoptosis and cell proliferation. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 180-186.	2.4	31